Primecap Management Co. CA Has $89.11 Million Holdings in IQVIA Holdings Inc. $IQV

Primecap Management Co. CA trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 469,161 shares of the medical research company’s stock after selling 74,410 shares during the period. Primecap Management Co. CA’s holdings in IQVIA were worth $89,112,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of IQV. Brighton Jones LLC grew its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC boosted its position in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at about $514,000. Envestnet Asset Management Inc. increased its position in IQVIA by 31.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 633,262 shares of the medical research company’s stock valued at $99,796,000 after buying an additional 150,582 shares in the last quarter. Finally, Transcend Capital Advisors LLC acquired a new position in IQVIA during the 2nd quarter worth approximately $203,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQV opened at $170.21 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market capitalization of $28.88 billion, a price-to-earnings ratio of 21.66, a P/E/G ratio of 1.56 and a beta of 1.37. The firm’s fifty day moving average price is $213.03 and its two-hundred day moving average price is $207.86.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the prior year, the company posted $3.12 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Evercore reissued an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a research note on Thursday, February 5th. Mizuho set a $215.00 target price on IQVIA in a report on Monday. Barclays decreased their price target on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, February 6th. UBS Group dropped their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Finally, Morgan Stanley set a $240.00 price objective on shares of IQVIA in a report on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $231.80.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.